SCHEMBL5458257

SCHEMBL5458257

CCC(C(=O)O)N(Cc1ccc(OCCN(C)c2ncccn2)cc1)C(=O)Oc1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 2/20 0.42
PPARG P37231 8/20 0.41
PPARA Q07869 4/20 0.41
BLM P54132 2/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GMNN O75496 1/20 0.39
EGFR P00533 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRB3 P13945 1/20 0.39
ADRA2B P18089 1/20 0.39
NFKB1 P19838 1/20 0.39
TACR2 P21452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461251 0.92 PPARG (0.50) LMNAMAPTTSHRPPARGPPARA
SCHEMBL5430372 0.82 KCNH2 (0.44) SMN1; SMN2KCNH2
SCHEMBL6513163 0.81 PPARA (0.58) LMNAMAPTTSHRPPARGPPARA
SCHEMBL5422779 0.79 TAS2R14 (0.45) MAPTTSHRPPARGPPARASMN1; SMN2
SCHEMBL5430605 0.79 PPARG (0.45) LMNAPPARGPPARAMEN1KMT2A
SCHEMBL5440280 0.78 PPARA (0.57) PPARGPPARA
SCHEMBL5431844 0.78 PPARG (0.44) LMNAMAPTPPARGPPARASMN1; SMN2
SCHEMBL6505582 0.78 PPARG (0.54) LMNAPPARGPPARA
SCHEMBL5427770 0.78 SMPD1 (0.44) MAPTPPARGPPARAMEN1KMT2A
SCHEMBL5423631 0.77 SMN1; SMN2 (0.53) LMNAMAPTTSHRPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005049589-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES CADILA HEALTHCARE LIMITED (IN) 2005-06-02 WO claimed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
WO-2005049589-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES CADILA HEALTHCARE LIMITED (IN) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 LMNA 949/4885MAPT 162/4885TSHR 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.